ABUS today
$3.88+$0.06 (+1.57%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourBullish
1 hourSymmetric Triangle
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns down below $1.60
Key levels
Resistance$4.38
Resistance$4.05
Support$3.79
Support$3.59
Latest news & SEC filings
EarningsArbutus Biopharma Posts Q3 2026 Results
EarningsArbutus Biopharma posts $0.30 per-share profit for third quarter, topping $(0.03) forecast
SEC FilingArbutus Biopharma Corp filed a report on a major company event (Form 8-K)
All ABUS news →About Arbutus Biopharma
Arbutus Biopharma develops medicines for chronic hepatitis B. Its main candidates are imdusiran, an RNA interference therapy given by injection, and AB-101, a pill that blocks a checkpoint protein to help the immune system fight the virus. The company also owns lipid nanoparticle delivery technology that it licenses to other parties and is pursuing patent disputes over use of that technology in COVID-19 vaccines.
Based on the company's 10-K filed Mar 23, 2026.
Nasdaq · Healthcare
Arbutus Biopharma Corp (ABUS)
What Is the Price Target for ABUS?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ABUS a Buy or Sell Right Now?
Thesis
- •Revenue growing 128.2% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ABUS.
Start Free Trial →Is ABUS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, PEG
Fair Value
$7.20
59
Moat Score
NARROW
4/9
Piotroski Score
2.8
Altman Z-Score
What Is Smart Money Doing with ABUS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Beardsley Robert A | director | Sale | 17,948 | $90K | Oct 1, 2026 |
| Nguyen Tuan | officer | Sale | 48,081 | $240K | Oct 1, 2026 |
| Sawhney Roger | director | Sale | 17,142 | $86K | Oct 1, 2026 |
| Androski Lindsay | director officer | Sale | 24,655 | $123K | Oct 1, 2026 |
| Androski Lindsay | director officer | Buy | 116,408 | $373K | Sep 18, 2026 |
| Androski Lindsay | director officer | Buy | 10,456 | $46K | Sep 18, 2026 |
| Androski Lindsay | director officer | Sale | 82,527 | $418K | Sep 18, 2026 |
| Nguyen Tuan | officer | Buy | 265,625 | $927K | Sep 18, 2026 |
| Nguyen Tuan | officer | Buy | 27,475 | $121K | Sep 18, 2026 |
| Nguyen Tuan | officer | Sale | 206,637 | $1.0M | Sep 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ABUS Growth Story
Revenue YoY
128.2%
3yr Revenue CAGR
-28.8%
EPS Growth YoY
55.26%
FCF Growth YoY
39.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for ABUS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ABUS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:04 | $3.88 | 4,244 | $$16K | SELL |
| 21:00:04 | $3.88 | 1,461 | $$6K | SELL |
| 21:00:00 | $3.88 | 3,170 | $$12K | SELL |
| 20:59:55 | $3.88 | 1,400 | $$5K | MIDPOINT |
| 20:59:55 | $3.88 | 3,500 | $$14K | MIDPOINT |
5 dark pool trades shown · $$53K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ABUS
PREVIEWSEPT Investing provides real-time options flow tracking for ABUS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $4.5 | Jan 15 | 65 | $$14 | 1 | SWEEP |
| PUT | $4.5 | Jan 15 | 65 | $$268 | 2 | SWEEP |
| PUT | $4.5 | Jun 17 | 218 | $$296 | 2 | SWEEP |
| PUT | $4.5 | Jan 15 | 65 | $$274 | 2 | SWEEP |
| PUT | $4.5 | Jun 17 | 218 | $$450 | 3 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About ABUS
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ABUS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $ABUS (Arbutus Biopharma Corp) Price: $5.22 | Zone: $4.32 to $5.34 Conviction: HIGH Near resistance (88% of range) — breakout watch. Strong positive news (4+ vs 0-)
Join 3,500+ traders discussing ABUS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Arbutus Biopharma Corp (ABUS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ABUS — frequently asked questions
What is ABUS stock price today?
Arbutus Biopharma Corp (ABUS) is at $3.88, up 1.57% (+$0.06) at the Nov 11, 2026 close.
Why is ABUS stock moving today?
Latest ABUS news — Nov 10, 2026: Arbutus Biopharma Posts Q3 2026 Results · Nov 10, 2026: Arbutus Biopharma posts $0.30 per-share profit for third quarter, topping $(0.03) forecast
What do analysts rate ABUS?
Analyst ratings for ABUS: 2 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did ABUS beat earnings?
ABUS last reported on Aug 12, 2026: EPS -$0.03 vs -$0.02 expected — a miss of 50.0%.
What is ABUS's P/E ratio?
ABUS trades at a P/E of 4.7 vs a Healthcare average of 17.1.
Does ABUS pay a dividend?
ABUS does not currently pay a dividend.
How much debt does ABUS have?
Arbutus Biopharma Corp reported $0M of debt and $19M of cash (Jun 30, 2026).
What are ABUS support and resistance levels?
Support: $3.79, $3.59, $3.31. Resistance: $4.05, $4.38, $4.74.
What are insiders doing with ABUS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ABUS?
Nov 10, 2026: Arbutus Biopharma Posts Q3 2026 Results · Nov 10, 2026: Arbutus Biopharma posts $0.30 per-share profit for third quarter, topping $(0.03) forecast · Nov 10, 2026: Arbutus Biopharma Corp filed a report on a major company event (Form 8-K)